These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9123215)

  • 1. Rejection of Fas ligand-expressing grafts.
    Seino K; Kayagaki N; Fukao K; Okumura K; Yagita H
    Transplant Proc; 1997; 29(1-2):1092-3. PubMed ID: 9123215
    [No Abstract]   [Full Text] [Related]  

  • 2. Transplantation of CD95 ligand-expressing grafts: influence of transplantation site and difficulty in protecting allo- and xenografts.
    Seino K; Kayagaki N; Tsukada N; Fukao K; Yagita H; Okumura K
    Transplantation; 1997 Oct; 64(7):1050-4. PubMed ID: 9381528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege.
    Gregory MS; Repp AC; Holhbaum AM; Saff RR; Marshak-Rothstein A; Ksander BR
    J Immunol; 2002 Sep; 169(5):2727-35. PubMed ID: 12193747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of Fas ligand to cardiac allograft rejection.
    Seino K; Kayagaki N; Bashuda H; Okumura K; Yagita H
    Int Immunol; 1996 Sep; 8(9):1347-54. PubMed ID: 8921411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice.
    Behrens CK; Igney FH; Arnold B; Möller P; Krammer PH
    J Immunol; 2001 Mar; 166(5):3240-7. PubMed ID: 11207278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skin graft rejection elicited by beta 2-microglobulin as a minor transplantation antigen involves multiple effector pathways: role of Fas-Fas ligand interactions and Th2-dependent graft eosinophil infiltrates.
    Surquin M; Le Moine A; Flamand V; Nagy N; Rombaut K; Demoor FX; Stordeur P; Salmon I; Guéry JC; Goldman M; Abramowicz D
    J Immunol; 2002 Jul; 169(1):500-6. PubMed ID: 12077281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perforin- and Fas-dependent mechanisms of natural killer cell-mediated rejection of incompatible bone marrow cell grafts.
    Taylor MA; Ward B; Schatzle JD; Bennett M
    Eur J Immunol; 2002 Mar; 32(3):793-9. PubMed ID: 11870623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of CD95 ligand-mediated inflammation.
    Seino K; Tun T; Ohshima N; Hamada H; Yoshino K; Ikeda S; Fukunaga K; Taniguchi H; Takada Y; Yuzawa K; Otsuka M; Todoroki T; Fukao K
    Transplant Proc; 2000 Nov; 32(7):2038-9. PubMed ID: 11120056
    [No Abstract]   [Full Text] [Related]  

  • 9. Cutting edge: a novel role for Fas ligand in facilitating antigen acquisition by dendritic cells.
    Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Okada S; Tokuhisa T; Sakiyama S; Tagawa M
    J Immunol; 2002 Sep; 169(5):2241-5. PubMed ID: 12193688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fas and Fas ligand in discordant xenogeneic antibody-dependent cell-mediated cytotoxicity.
    Fujiwara I; Nakajima H; Matsuda T; Mizuta N; Yamagishi H; Oka T
    Transplant Proc; 1998 Aug; 30(5):2488-90. PubMed ID: 9723550
    [No Abstract]   [Full Text] [Related]  

  • 11. CD95 ligand in graft rejection.
    Yagita H; Seino K; Kayagaki N; Okumura K
    Nature; 1996 Feb; 379(6567):682. PubMed ID: 8602212
    [No Abstract]   [Full Text] [Related]  

  • 12. A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege.
    Gregory MS; Koh S; Huang E; Saff RR; Marshak-Rothstein A; Mukai S; Ksander BR
    Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2495-502. PubMed ID: 15980241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptosis and the expression of Fas and Fas-ligand antigen after orthotopic liver transplantation.
    Tannapfel A; Kohlhaw K; Schwarz R; Wenzke M; Köckerling F; Ebelt J; Hauss J; Wittekind C
    Transplant Proc; 1998 Aug; 30(5):2358-9. PubMed ID: 9723503
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunology. Ways around rejection.
    Vaux DL
    Nature; 1995 Oct; 377(6550):576-7. PubMed ID: 7566165
    [No Abstract]   [Full Text] [Related]  

  • 15. Expression of Fas/Fas ligand and apoptosis induction during renal allograft rejection.
    Matsuno T; Sasaki H; Nakagawa K; Okada Y; Endo A; Fujiwara T; Oishi M; Saito S; Yagi T; Haisa M; Tanaka N
    Transplant Proc; 1998 Nov; 30(7):2947-9. PubMed ID: 9838299
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice.
    Lau HT; Yu M; Fontana A; Stoeckert CJ
    Science; 1996 Jul; 273(5271):109-12. PubMed ID: 8658177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrarenal display of cytotoxic attack molecules during rejection.
    Sharma VK; Bologa RM; Li B; Xu GP; Lagman M; Mouradian J; Wang J; Serur D; Rao VK; Suthanthiran M
    Transplant Proc; 1997; 29(1-2):1090-1. PubMed ID: 9123214
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro prevention of cell-mediated xeno-graft rejection via the Fas/FasL-pathway in CrmA-transducted porcine kidney cells.
    Fujino M; Li XK; Suda T; Hashimoto M; Okabe K; Yaginuma H; Mikoshiba K; Guo L; Okuyama T; Enosawa S; Amemiya H; Amano T; Suzuki S
    Xenotransplantation; 2001 May; 8(2):115-24. PubMed ID: 11328582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated rejection of Fas ligand-expressing heart grafts.
    Takeuchi T; Ueki T; Nishimatsu H; Kajiwara T; Ishida T; Jishage K; Ueda O; Suzuki H; Li B; Moriyama N; Kitamura T
    J Immunol; 1999 Jan; 162(1):518-22. PubMed ID: 9886428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of Fas and Fas ligand interaction in allogeneic hepatocyte rejection in the spleen.
    Kawahara T; Kasai S; Yagita H; Kato K; Sawa M; Nakajima A; Azuma M; Okumura K; Futagawa S; Mito M
    Transplant Proc; 1997 Jun; 29(4):2187-8. PubMed ID: 9193582
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.